The assessment of effect of Tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia
Phase 3
- Conditions
- Benighn Prostatic Hypertrophia.Benign Prostatic Hypertrophia
- Registration Number
- IRCT201008094541N1
- Lead Sponsor
- Guilan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 132
Inclusion Criteria
patients with score > 8 and without any indications for prostatic surgery such as recurrent retention, persistent gross hematuria, permanent urinary infections associated with BPH, renal function failure and hydronephrosis, bladder stone due to BPH, under previous standard medical treatment with prazocine (max doze 10mg) daily with or without Finastride (5 mg, daily, for 3 months). Response to medication should be in plateau level
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method International score of prostatic signs & symptoms. Timepoint: Baseline and 3 months after the intervention. Method of measurement: IPSS: International Prostatic Symptom Score.
- Secondary Outcome Measures
Name Time Method rinary satisfaction. Timepoint: Baseline and 3 months after the intervention. Method of measurement: (IPSS: International Prostatic Symptom Score).;Maximum urinary flow. Timepoint: Baseline and 3 months after the intervention. Method of measurement: Uroflometry.